Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...

In the past week, bluebird bio named new leaders after its acquisition, Dyne secured a debt deal and ProFound Therapeutics ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...